← Search & browse all drugs
CARDIOVASCULAR SYSTEM › VASOPROTECTIVES › CAPILLARY STABILIZING AGENTS › Bioflavonoids
rutoside, combinations
C05CA51
Forms & Strengths
- Oral tablets: Rutoside 450 mg / Ascorbic acid 50 mg
- Oral capsules: Rutoside 50 mg / Aescin 30 mg (combinations vary by region)
- Topical gel: Rutoside combined with heparinoid or NSAIDs
Adult Dosing
- Chronic venous insufficiency: 1 to 2 tablets daily in divided doses
- Hemorrhoids (acute attack): Higher initial loading doses (e.g., up to 4 tablets daily), tapering over several days
- Topical formulations: Apply a thin layer to the affected area 2 to 3 times daily
Pediatric Dosing
- Safety and efficacy not established in pediatric populations
- Use in children under 18 years is generally not recommended unless specifically directed by a specialist
Indications
- Symptomatic treatment of chronic venous insufficiency (leg pain, heaviness, nocturnal cramps)
- Adjunctive management of hemorrhoidal disease and acute hemorrhoid symptoms
- Relief of capillary fragility, edema, and superficial venous inflammation
Mechanism of Action
- Exerts venotonic and vasoprotective effects by increasing venous tone and reducing vascular permeability
- Decreases leukocyte adhesion and activation in the microcirculation, mitigating capillary hyperpermeability
- Scavenges free radicals and exhibits antioxidant activity (enhanced when combined with ascorbic acid)
Contraindications
- Hypersensitivity to rutoside (rutin), related flavonoids, or any component of the combination product
- Severe renal impairment (for specific combination products containing high-dose ascorbic acid or NSAIDs)
Adverse Reactions
- Mild gastrointestinal disturbances (nausea, epigastric discomfort, diarrhea)
- Allergic skin reactions (rash, pruritus, urticaria) in sensitive individuals
- Headache or dizziness (rare)
Drug Interactions
- Potential enhancement of anticoagulant or antiplatelet therapy bleeding risk (when combined with systemic anticoagulants or high-dose NSAIDs)
- Ascorbic acid combinations may interfere with laboratory tests (e.g., stool occult blood, urine glucose)
- No major cytochrome P450-mediated drug interactions are clinically established
Curated Content: Needs Vetting Before Put to Clinical Use